Sara Labiano Almiñana-rekin lankidetzan egindako argitalpenak (20)

2019

  1. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

2018

  1. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes

    Cancer Immunology Research, Vol. 6, Núm. 1, pp. 69-78

  2. Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)

    OncoImmunology, Vol. 7, Núm. 1

  3. Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) Costimulation

    Cancer Immunology Research, Vol. 6, Núm. 7, pp. 798-811

2017

  1. Cellular immunotherapies for cancer

    OncoImmunology, Vol. 6, Núm. 5

2016

  1. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming

    Cancer Research, Vol. 76, Núm. 20, pp. 5994-6005

  2. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy

    European Journal of Immunology, Vol. 46, Núm. 3, pp. 513-522

  3. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism

    OncoImmunology, Vol. 5, Núm. 1

  4. Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and anti-CD137 monoclonal antibodies

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. 524-536

  5. Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)

    Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936

2015

  1. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, Núm. 24, pp. 7551-7556

  2. Functional expression of CD137 (4-1BB) on T helper follicular cells

    OncoImmunology, Vol. 4, Núm. 12

  3. Immune response regulation in the tumor microenvironment by hypoxia

    Seminars in Oncology, Vol. 42, Núm. 3, pp. 378-386

  4. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

    Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478

  5. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

    Leukemia

  6. Virotherapy with a Semliki forest virus-based vector encoding IL12 synergizes with PD-1/PD-L1 blockade

    Cancer Immunology Research, Vol. 3, Núm. 5, pp. 449-454

2014

  1. Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer

    OncoImmunology, Vol. 3, Núm. 1

  2. Orchestrating immune check-point blockade for cancer immunotherapy in combinations

    Current Opinion in Immunology, Vol. 27, Núm. 1, pp. 89-97

2013

  1. Better performance of CARs deprived of the PD-1 brake

    Clinical Cancer Research, Vol. 19, Núm. 20, pp. 5546-5548

  2. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6151-6162